Felicia Roncolato, Madeleine T King, Rachel L O'Connell, Yeh Chen Lee, Florence Joly, Felix Hilpert, Anne Lanceley, Yoshio Yoshida, Jane Bryce, Paul Donnellan, Amit Oza, Elisabeth Avall-Lundqvist, Jonathan S Berek, Jonathan A Ledermann, Dominique Berton, Jalid Sehouli, Marie-Christine Kaminsky, Martin R Stockler, Michael Friedlander
OBJECTIVE: To describe the baseline symptom burden(SB) experienced by patients(pts) with recurrent ovarian cancer(ROC) prior and associations with progression free survival (PFS) and overall survival (OS). METHODS: We analysed baseline SB reported by pts. with platinum resistant/refractory ROC (PRR-ROC) or potentially‑platinum sensitive ROC receiving their third or greater line of chemotherapy (PPS-ROC≥3) enrolled in the Gynecologic Cancer InterGroup - Symptom Benefit Study (GCIG-SBS) using the Measure of Ovarian Symptoms and Treatment concerns (MOST)...
February 26, 2024: Gynecologic Oncology